iSPERSE

June 15, 2017June 15, 2017

Pulmatrix Strikes Licensing Deal to Gain Access to RespiVert’s Lung Disease Treatments

Pulmatrix has signed a licensing agreement with RespiVert, a subsidiary of Janssen Biotech, to gain access to RespiVert’s portfolio of kinase inhibitors for treating lung diseases. Kinase inhibitors act by blocking ... Read more

May 10, 2017May 11, 2017

Pulmatrix Receives US Patent for PUR0200, an Inhaled Formulation for Lung Diseases

COPD, News

Pulmatrix has received a U.S. patent for PUR0200, an inhaled formulation of tiotropium bromide for lung diseases such as chronic obstructive pulmonary disease (COPD). The company said the powder it developed does a better ... Read more

August 22, 2016August 22, 2016

FDA Grants Orphan Drug Status to Pulmatrix’s PUR1900 for Cystic Fibrosis Fungal Lung Infections

Cystic Fibrosis, News

The U.S. Food & Drug Administration (FDA) has granted orphan drug designation to Pulmatrix‘s PUR1900, an inhaled drug for the treatment of pulmonary fungal infections in patients with cystic fibrosis (CF). ... Read more

July 25, 2016July 25, 2016

PUR0200, an Inhaled Bronchodilator for COPD, Shows Promise in Pilot Study

COPD, News

PUR0200, a new dry powder formulation being developed for the treatment of chronic obstructive pulmonary disease (COPD), has shown positive pharmacokinetic results in a Phase 1 pilot study. The results were ... Read more

September 14, 2015November 5, 2015

Pulmatrix To Present Promising Inhaled CF Therapy PUR1900 at Cystic Fibrosis Conference

Cystic Fibrosis, News

Pulmatrix, a biotechnology company developing new inhaled therapies to address pulmonary diseases through the company’s own clinically validated technology iSPERSE, recently announced that their lead investigational therapy for CF will ... Read more